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F O C U S O N M O L E C U L A R I M A G I N G
Insights into Trace Metal Metabolism in Health and Disease
from PET: ‘‘PET Metallomics’’
Joanna J. Bartnicka and Philip J. Blower
King’s College London, School of Biomedical Engineering and Imaging Sciences, St. Thomas’ Hospital, London, United Kingdom
Essential trace metals such as copper, zinc, iron, and manganese
perform critical functions in cellular and physiologic processes
including catalytic, regulatory, and signaling roles. Disturbed metal
homeostasis is associated with the pathogenesis of diseases such
as dementia, cancer, and inherited metabolic abnormalities. In-
tracellular pathways involving essential metals have been exten-
sively studied but whole-body fluxes and transport between
different compartments remain poorly understood. The growing
availability of PET scanners and positron-emitting isotopes of key
essential metals, particularly 64Cu, 63Zn, and 52Mn, provide new
tools with which to study these processes in vivo. This review high-
lights opportunities that now present themselves, exemplified by
studies of copper metabolism that are in the vanguard of a new
research front in molecular imaging: “PET metallomics.”
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Essential trace metals are important in many cellular and
physiologic processes, including ubiquitous enzymatic reactions
and protein folding. For example, copper-dependent enzymes in-
clude cytochrome-c oxidase, superoxide dismutase, and cerulo-
plasmin, which participate in aerobic respiration, antioxidant de-
fense, and hepatic iron release, respectively, all of which depend
on the redox activity of copper as it cycles between its 2 principal
oxidation states, Cu(I) and Cu(II). Zinc is essential for the catalytic
function and structure of many proteins with roles in, inter alia,
metabolism, gene regulation, chromatin structure, and neurotrans-
mission. Iron is essential in hemoglobin, respiration, and DNA and
RNA synthesis, whereas manganese is important to enzymes that
destroy reactive oxygen species and produce urea and nitric oxide
(1). In healthy states, metal homeostasis is tightly controlled, and its
deregulation is implicated as cause or consequence of many human
diseases. Mutations in copper transporters ATP7B and ATP7A
result in, respectively, Wilson’s disease (WD) (characterized by
copper overload) and Menkes disease (characterized by systemic
copper deficiency and fatal in childhood). Copper imbalance is
implicated in neurodegeneration and cancer, although whether as
cause or consequence is unclear. Abnormal zinc levels occur in
diabetes and cystic fibrosis, and both zinc and copper accumulate
in amyloid plaques in Alzheimer disease. The study of trace met-
als in biology and medicine, historically known as inorganic bio-
chemistry or bioinorganic chemistry, is growing in importance,
becoming fashionably known as ‘‘metallomics.’’
The structure and function of many metalloproteins containing
copper, zinc, and other trace metals are well characterized. The
routes through which these metals reach their sites of action
and become incorporated into their metalloproteins are less well
understood, but it is now clear that complex trafficking systems
exist in cells to ensure correct delivery while avoiding toxic
accumulation. Metal concentration in tissues can be measured
and mapped by highly sensitive techniques such as laser ablation
inductively coupled plasma mass spectrometry, but transport and
chaperoning pathways leading to these local concentrations—from
ingestion to site of action and excretion—are less well studied.
Metal ion–activated optical (2) and MRI (3) probes for cellular
and in vivo whole-body measurement of copper and zinc have been
described. However, these probes must react with the metal ions;
hence, they visualize exchangeable copper pools rather than copper
trafficking processes, and may themselves perturb the systems they
are probing. Dynamic, acute metal fluxes in the whole body that
give rise chronically to the endpoints represented by total copper
content of tissues are not amenable to study in vitro at the cellular
level. Practitioners of molecular imaging and nuclear medicine
will instinctively recognize these whole-body trafficking processes
as precisely those that their methods and instruments can help
elucidate.
UTILITY OF PET IMAGING TO MONITOR METAL
HOMEOSTASIS
Radioactive and stable metal isotopes have been used histor-
ically, without the advantages afforded by radionuclide imaging,
to delineate trafficking pathways between body compartments
for metals such as copper (Fig. 1). However, the need for tissue
sampling restricted their use in humans and required culling of
animals at predetermined time points. In vivo imaging with PET
circumvents these problems, allowing noninvasive, dynamic
measurements across the whole body. With growing availability
of PET scanners and rapidly developing methodology for pro-
ducing positron-emitting radioisotopes of key essential metals, it
is now increasingly feasible to use nuclear medicine techniques
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to address these challenges. Although this use of PET is in its
infancy, recent studies with 64Cu exemplify the potential, mark-
ing a path that can be followed to study other essential trace
metals.
PET IMAGING OF COPPER HOMEOSTASIS
64Cu has been routinely available in some research-oriented
PET centers for more than two decades. Chelator design for
64Cu radiolabeling of biomolecules and redox-active tracers is
advanced (4), but use of 64Cu to study the biologic behavior of
copper itself has been relatively scarce. 64Cu decays by 18% b1
emission with a half-life of 12.7 h, allowing imaging for days,
long enough to image both uptake in tissues and subsequent efflux
and excretion (unlike other positron-emitting copper radioiso-
topes: 60Cu, 61Cu, 62Cu). The small but growing literature describ-
ing its use in metallomics in health and in disease, particularly
WD, dementia, and cancer, are reviewed below.
WD
WD is caused by an autosomal recessive mutation in the ATP7B
gene. Loss of function of ATP7B disables copper incorporation into
ceruloplasmin and excretion via bile. The resulting systemic copper
overload causes liver dysfunction, severe neurologic symptoms, and
eye and kidney damage. Radiocopper has historically been used to
detect differences in copper metabolism between WD patients and
healthy individuals by measuring radioactivity in serum and excreta.
More recently, PET in mice 24 h after intravenous or oral admin-
istration of 64CuCl2 showed that ATP7B knockout increased tracer
liver uptake severalfold and decreased its biliary excretion, agreeing
with clinical manifestations of WD (5). Because many WD patients
present with neurologic or psychiatric symptoms, possibly linked to
disrupted cerebral copper homeostasis, 64CuCl2 PET has been used
to image brain copper fluxes in ATP7B knockout mice (6), reveal-
ing significant age-dependent differences from healthy controls.
However, brain uptake of 64Cu administered as CuCl2 is so low that
interpreting these changes is difficult. The acute changes observed
by PET did not correlate with total brain copper content measured
by inductively coupled plasma mass spectrometry, demonstrating
the need for complementary information from both methodolo-
gies to fully understand acute and chronic effects of disease on
whole-body copper homeostasis. Nevertheless, these animal stud-
ies suggest that 64Cu PET could become a clinical tool to assess
whole-body copper metabolism in humans to improve patient
management and reduce need for invasive liver biopsy. It could
complement genetic testing (which is challenging to interpret as
more than 300 disease-causing mutations of ATP7B have been
identified (7)) and monitor outcomes of treatments such as copper
chelation, gene therapy, and hepatocyte transplantation. PET im-
aging with 64Cu-histidine complex has been used in the rat model
of WD in the latter context (8).
Neurodegeneration
Growing evidence implicates zinc, iron, and copper in the
pathology of b-amyloid aggregation associated with Alzheimer
disease (AD)—the ‘‘metal hypothesis of AD’’ (9). The role of
these metals, whether cause, consequence, or merely red herring,
is poorly understood, and could potentially be illuminated by im-
aging brain metal fluxes. Peng et al. found no significant age-
dependent changes in brain copper uptake by 64CuCl2 PET in
healthy mice (10), again emphasizing the limitations of 64CuCl2
PET in brain due to low blood–brain barrier penetration. To cir-
cumvent this problem, others used 64Cu-GTSM, a lipophilic com-
plex that crosses the blood–brain barrier and passively enters cells,
by-passing copper trafficking mechanisms and barriers. It then
undergoes reductive dissociation to liberate 64Cu1, which, it is
presumed, feeds into intracellular copper trafficking pathways
and can be used to observe copper redistribution and efflux.
64Cu-GTSM PET and ex vivo quantification in a mouse model
of AD, bPP/PS1 (11), showed significantly higher uptake in the
brains of the AD mice than in controls (P 5 0.01) after 1 h. A
similar 64Cu-GTSM study (12) revealed an analogous difference
in another AD model, TASTPM transgenic mice, showing also
that 64Cu clearance from the brain between 30 min and 24 h was
faster, and heterogeneity of cerebral distribution was greater,
than in wild-type controls (Fig. 2). Interestingly, both groups
showed no correlation in regional distribution between 64Cu
uptake and Ab plaques. Use of 64Cu-GTSM highlights the im-
portance of evaluating alternatives to simple radiometal salts,
intravenous injection of which may not mimic native pathways
and which cannot visualize regions of low uptake, such as the
brain, in which uptake of 64Cu-acetate was more than 7-fold
lower than that of 64Cu-GTSM and was limited to the ventricular
areas (13).
Cancer
Copper metabolism is disrupted in various human cancers.
Plasma copper levels are elevated in some cancer patients,
possibly correlating with cancer progression (14), and increased
copper concentrations are found in tumor tissue. Copper is an
essential cofactor for proteins involved in tumorigenesis and can
modulate cancer cell proliferation, angiogenesis, and metastatic
progression in vitro. Pharmacologic manipulations of a ‘‘copper-
cancer axis’’ showed cytostastic effects in preclinical models (15).
Mouse hepatomas accumulated considerable 64Cu (16) on admin-
istration of radiocopper(II) salts. The study of copper trafficking in
FIGURE 1. Simplified model of whole-body copper absorption, distri-
bution and excretion, showing main identified copper carriers in blood.
Based on data from Linder (40).
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cancer is therefore worthwhile, particularly after identification of
the human high-affinity copper transporter 1 (hCTR1). PET with
intravenous 64CuCl2 was evaluated in athymic mice bearing hep-
atoma xenografts, with hCTR1 as its putative molecular target,
and later in mice bearing various human cancer xenografts includ-
ing prostate, hepatocellular carcinoma, melanoma, head and neck,
glioblastoma, and breast cancers (17,18), showing promise partic-
ularly in anatomic regions with low background 64CuCl2 uptake
such as the pelvic area and brain. Some of these studies confirmed
higher hCTR1 expression in malignant cells than in nonmalignant
or background tissue. Although 1 study in 5 cancer cell lines found
no correlation of 64CuCl2 uptake with hCTR1 expression (mea-
sured by quantitative polymerase chain reaction) (19), others
showed that hCTR1 knockdown in PC3 prostate cancer xenografts
reduced 64Cu uptake from 7.21 to 4.02 percentage injected dose
per gram (P , 0.001) (20) and hCTR1 overexpression in a MDA-
MB-231 breast cancer model increased it from 2.58 to 5.37 per-
centage injected dose per gram (P , 0.05) (21). These observa-
tions suggest that hCTR1 is important, but not the sole player, in
the in vivo tumor uptake of copper.
Clinical Studies in Cancer Patients
64CuCl2 PET has recently been evaluated for tumor imaging
in humans, detecting primary and secondary lesions in 18 of 19
patients with glioblastoma multiforme (22) (although uptake may
have been due to blood–brain barrier disruption rather than spe-
cific copper transport pathways). In prostate cancer, the low uri-
nary excretion of 64CuCl2 (23) allowed local tumors to be readily
delineated by PET in a preliminary study of 7 patients. A larger
study in 50 prostate cancer patients (24) demonstrated detection of
tumor recurrence and lymph node metastases (Fig. 3) with greater
sensitivity than 18F-choline, especially in patients with low pros-
tate-specific antigen levels. Further trials of 64CuCl2 PET compar-
ing it with established prostate cancer tracers, and studies of the
specific pathways involved, are warranted and encouraged by lack
of observed adverse effects of the 64CuCl2 doses (200–250 MBq)
used. Dosimetry estimates showed that several GBq could be ad-
ministered before exceeding threshold radiation doses to the liver
(the critical organ) (23–25).
64Cu PET visualization of copper ho-
meostasis in tumors could aid development
of new treatment strategies, exploiting the
putative roles of copper in carcinogene-
sis. Despite encouraging preclinical results,
clinical trials involving cancer treatment
with copper chelators, or combining copper
supplementation with ionophores, mostly
failed to demonstrate clinical efficacy (15).
Patient stratification using 64Cu PET to vi-
sualize abnormal copper homeostasis may
improve the sensitivity of such trials (26).
The combined b, positron, and Auger
electron emissions of 64Cu offer applica-
tions in radionuclide therapy, which could
be further supported by growing availabil-
ity of the longer half-life b-emitter 67Cu.
Despite promising tumor reductions in
mice bearing xenografts of human mela-
noma (27) and glioblastoma (28), evidence
of therapeutic effectiveness of 64CuCl2 in
human subjects is sparse (29). Dosimetric
analysis in the prostate cancer trial (25) suggested that tumor
absorbed doses from 64Cu would be too low for therapeutic ben-
efit, but the analysis did not include effects of Auger electrons and
was not extended to 67Cu.
PERSPECTIVE
64CuCl2 PET is increasingly being used to assess whole-body
copper fluxes in disease states caused by, or linked to, altered
copper homeostasis, potentially leading to improved diagnosis
and complementing or replacing biopsies (which are invasive
and prone to anatomically incorrect sampling) and genetic testing
(which is challenging in diseases with high genotypic variation).
This field is immature, and experimental design and data interpre-
tation are understandably naı¨ve. Data on real-time trafficking of
copper must be complemented by measurements of the conse-
quent total copper content in tissues over long periods; it is pos-
sible that large differences in total copper content between tissues
could arise from very small, perhaps undetectable, differences in
acute trafficking. It is also clear that intravenous administration of
ionic 64Cu (e.g., copper(II) chloride or acetate) alone will not
provide full understanding of copper trafficking mechanisms as
it probably does not reflect native trafficking pathways. Imagina-
tive variations in the chemical form and route of administration
must be devised.
FIGURE 3. Axial (A) and coronal (B) PET/CT images of pelvic area in
prostate cancer patient (Gleason grade 4 1 3) 60 min after injection of
200– 250 MBq of 64CuCl2, demonstrating tracer uptake in foci of local
relapse (arrow). (Reprinted with permission of (24).)
FIGURE 2. PET/CT maximum-intensity-projection images showing differences in the regional
brain uptake of 64Cu in wild-type and TASTPM AD model mice, 30 min and 24 h after intravenous
injection of 64Cu-GTSM. (Reprinted with permission of (12).)
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Progress made in 64Cu PET is attributable to the established
production methods and favorable imaging properties of 64Cu,
and the proliferation of preclinical PET scanners. New radionu-
clide production methods are now extending this opportunity to
other essential metals, particularly zinc, manganese and iron. The
first animal and human zinc radioisotope studies used 65Zn, which
due to its long half-life (243.7 d) presents little potential for im-
aging. 62Zn (half-life, 9.2 h; 8.4% positron yield) decays to the
positron-emitting copper radioisotope 62Cu (half-life, 9.7 min), so
that most positrons detected in PET scans would be from the
daughter 62Cu (Table 1), confounding image interpretation. A
promising radioisotope without this problem is 63Zn (half-life,
38.47 min). De Grado et al. developed production of 63Zn-citrate
by proton-irradiating isotopically enriched 63Cu (30), described its
biodistribution in mice, and performed a preliminary clinical study
with intravenous 63Zn-citrate in 6 healthy human subjects and 6
with AD (31), confirming high uptake in the liver and pancreas
and low but detectable brain accumulation previously seen in
animals. Efflux kinetics from brain regions showed significant
differences between healthy and AD patients, inviting future re-
search on imaging brain zinc homeostasis in neurodegeneration.
The availability of 63Zn, albeit limited to locations with an on-site
cyclotron, allows imaging of zinc trafficking in the many diseases
in which zinc is implicated (e.g., diabetes, dementia, hypertension,
and prostate cancer).
The recent development of a simple cyclotron-based production
of 52Mn (half-life, 5.59 d), hitherto used only for antibody (32),
liposome, and cell (33) labeling, offers the possibility to study
manganese biochemistry in vivo. Paramagnetic Mn21, which has
been used as MRI contrast to trace neuronal connection and repair,
is limited by the high, potentially neurotoxic concentration re-
quired, but recently PET with 52Mn21 was evaluated for similar
purposes (34). Whole-body biodistribution of 52Mn and the
shorter-lived 51Mn (half-life, 45.59 min), administered as MnCl2,
has been described in rodents (32,34–36), showing high uptake in
the pancreas, which differed between healthy, obese, and diabetic
mouse models. This warrants further evaluation of radiomanga-
nese PET for imaging functional b-cell mass (36).
52Fe (half-life, 8.28 h), 59Fe (half-life, 44.5 d), and 55Fe (half-
life, 2.73 y) have historically (since the 1960s) been used to visu-
alize bone marrow function in patients and to assess iron turnover
and organ uptake (37). Of these radioisotopes, only 52Fe emits
positrons, and interpretation of scans is complicated by the
positron emission of the daughter 52mMn. It has been used to track
Fe-hydroxide polysaccharides by PET in animals and humans
(38). 52Fe-citrate was used in a small clinical study to delineate
differences in brain iron metabolism between healthy and WD
patients (39).
The examples above highlight the opportunity to use trace metal
PET probes to help understand the role of trace metals in health
and disease, to diagnose disease and monitor therapy outcomes
longitudinally. With appropriate animal models and choice of
administered chemical form, this could lead to new therapeutic
strategies and methods to assess their effectiveness in patients by
observing their effects on metal fluxes in vivo. These early studies
demonstrate the growing feasibility of using PET to visualize
metal trafficking pathways in vivo at the whole-body level,
opening new exciting research avenues in the emerging field of
PET metallomics.
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